Literature DB >> 23389918

FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

Fábio Morato de Oliveira1, Carlos Eduardo Miguel, Antônio Roberto Lucena-Araujo, Ana Silvia Gouvêa de Lima, Roberto Passetto Falcão, Eduardo Magalhães Rego.   

Abstract

We investigated the prevalence of TET2 deletion by using a new FISH probe in a cohort of 362 Brazilian patients with myeloid neoplasms and their association with cytogenetic information (G-banding analysis). Normal karyotype was observed in 45.8 % of MDS (n = 44), 43.8 % of AML (n = 39) and 46.3 % of MPN (n = 82). Abnormalities of 4q24 (deletions, translocations or inversions) were associated with another chromosomal abnormality in four patients by G-banding analysis (2 MDS, 1 AML and 1 MPN). Interphase FISH analysis revealed deletion of TET2 in 21 patients (6 patients with abnormal karyotype and in 15 patients with normal karyotype). arrayCGH analysis revealed a cryptic deletion of the region 4q24 in all eight patients selected with myeloid malignancies (3 MDS, 1 AML and 4 MPN). Considering the significantly high cost of determining the mutational status of TET2 in patient samples by using conventional sequencing methods and sometimes the lack of regular use of SNP/aCGH array methodologies, FISH for the detection of TET2 abnormalities may become a potentially useful clinical tool. The search for alterations in TET2 gene may be important for the prediction of prognosis in normal/altered AML patients' karyotype or in the disease evolution of patients with MNP and MDS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389918     DOI: 10.1007/s12032-013-0483-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Authors:  Lurdes Zamora; Marisol Xandri; Olga Garcia; Siliva Marcé; Blanca Xicoy; Isabel Granada; José-Tomás Navarro; Fuensanta Millá
Journal:  Am J Clin Pathol       Date:  2012-04       Impact factor: 2.493

2.  FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples.

Authors:  Daniela Soriano Pignataro; Omar Abdel-Wahab
Journal:  Leuk Res       Date:  2011-09-13       Impact factor: 3.156

3.  Role of TET2 mutations in myeloproliferative neoplasms.

Authors:  Elodie Pronier; François Delhommeau
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 4.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 5.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival.

Authors:  Daniel T Starczynowski; Suzanne Vercauteren; Adele Telenius; Sandy Sung; Kaoru Tohyama; Angela Brooks-Wilson; John J Spinelli; Connie J Eaves; Allen C Eaves; Douglas E Horsman; Wan L Lam; Aly Karsan
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

7.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

8.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

9.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Authors:  Franz X Schaub; Renate Looser; Sai Li; Hui Hao-Shen; Thomas Lehmann; Andre Tichelli; Radek C Skoda
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

10.  Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.

Authors:  Joseph Tripodi; Ronald Hoffman; Vesna Najfeld; Rona Weinberg
Journal:  Cancer Manag Res       Date:  2010-09-17       Impact factor: 3.989

View more
  2 in total

1.  TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.

Authors:  Hongxia Yao; Mengling Duan; Lie Lin; Congming Wu; Xiangjun Fu; Hua Wang; Li Guo; Wenting Chen; Li Huang; Dan Liu; Ruo Rao; Shuwen Wang; Yipeng Ding
Journal:  Oncotarget       Date:  2017-03-14

2.  A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera.

Authors:  Eigil Kjeldsen
Journal:  Cancers (Basel)       Date:  2018-06-25       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.